CASI Pharmaceuticals FY25 net loss widens to US$48.06 million; revenue falls 27.3% to US$20.71 million

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc.

CASIF

0.00
  • CASI Pharmaceuticals posted revenue of US$20.7 million, down 27.3% year over year, while net loss widened to US$48.1 million from US$39.3 million.
  • Loss from operations widened to US$45 million, with general and administrative expense rising to US$28.3 million on higher legal fees of US$7.6 million tied to ongoing arbitrations.
  • Net cash used in operating activities improved to US$20.8 million from US$29.2 million, while cash and cash equivalents fell to US$5.6 million at year-end from US$13.5 million.
  • Company said NMPA did not approve renewal of FOLOTYN import drug registration license, prompting it to cease sales in China, while NMPA cleared marketing approval for MAFALAN in May 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-061632), on May 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.